Galapagos Returns Investigational Drug to Molecure

Molecure, a biotech company that is developing small molecule drugs for treatment of multiple incurable diseases, has regained full rights to OATD-01, its dual chitinase inhibitor, from Galapagos.

Galapagos, which is now focused on developing CAR-T therapies, is pulling out of a November 2020 partnership with Molecure and returning rights to the company’s investigational treatment for idiopathic pulmonary fibrosis and other diseases with a fibrotic component.

Molecure said it is considering going back to its original plan, which was to develop OATD-01 for treatment of patients with the inflammatory disease sarcoidosis.